By Sanji Bhal, Director of Marketing & Communications
Each year around this time we release a new version of our software, and this year is no different. As I sit down to write about the v2019 updates to our Spectrus and Percepta Platforms, I find myself thinking about the culmination of customer feedback, the expertise of our worldwide team, the milestone of our 25th anniversary, and the meticulous planning needed to get here.
As we focus on staying ahead of our customers’ scientific and technology needs, I think it’s of utmost importance to not only explain what’s new, but also highlight how the new functionalities will impact you – our user. Earlier this year we introduced Katalyst D2D and Percepta Portal to the world, and have since focused our development efforts on aligning with industry standard architecture. We’ve done so in v2019 through:
- Enhancements to processing and analysis tools for NMR and LC/MS data
- Continued development of chemical nomenclature
- Support for the breadth of Chemistry, Manufacturing, and Controls (CMC) workflows in pharmaceutical development in Luminata
- Upgrading our entire line of Percepta and Spectrus software solutions to 64-bit architecture
Here’s a closer look:
Luminata enables process development teams to make the right call the first time by integrating all project materials in order to translate data into information and knowledge. Now that Luminata has transitioned from impurity management to a CMC decision support tool, the software capabilities have expanded to cover new principle functionality areas, including:
Batch Genealogy—you will be able to track each batch created for a given process, either by internal or external manufacturing sources. Scientists will also be able to easily attach analytical and compositional results to make important supply chain decisions and view quantitative impurity tracking trends.
Formulation Development—Luminata can now be used to manage formulation development and accelerate the transition from drug substance to drug product by integrating analytical and process data in a single location that is searchable across the entire product lifecycle.
Drug Product & Drug Substance Stability—intuitively represent API forced degradation schemes under various conditions and inform the development of stability indicating methods through easily assembled degradation maps, associated spectroscopic characterization data, and kinetic plots.
Overall, the v2019 updates to Luminata will provide users with a single organizational source for process scheme, impurity control, formulation development, drug stability, and batch genealogy information, all while assembling data in accordance with Quality by Design (QbD) regulatory requirements.
Spectrus Platform Updates
Version 2019 updates to the Spectrus platform include an expansion of instrument vendor data format support and several enhancements across the analytical techniques and workflows supported by Spectrus applications:
NMR—users will now be able to streamline the analysis of highly complex mixtures better than ever before; work more easily with series of data through improved data visualization; and benefit from faster, more accurate prediction of NMR spectra.
LC/MS—in response to MS technology enhancements and customer requests, v2019 software offers greater flexibility in the analysis and display of MSn data. With new data analysis features, users will have independent control of chromatograms in hyphenated (LC/MS) datasets, greater flexibility in data analysis and annotation of MSn spectra, and the ability to automatically create MSn component spectra when a chemical structure is manually assigned to a component. With new data display features, users will be able to undock MSn spectral panes for flexible visualization and review.
Method Development and Optimization—in addition to expanded method screening, optimization, and reporting options for reversed phase separations, our chromatography applications now provide greater support for mixed mode and HILIC experiments.
The latest enhancements to our Spectrus platform will continue to make ACD/Spectrus a foundation for collecting and assembling related chemical, structural, and analytical data to generate useful insights, and support efficient decision-making.
Percepta Platform Updates
Our Percepta platform, built for powerful in-silico predictions offers fast, accurate PhysChem and ADME/Tox predictions from structure, powerful tools for data analysis, and decision support. Following the introduction of Percepta Portal earlier this year, the desktop applications have seen an upgrade to 64-bit architecture keeping some of ACD/Labs’ earliest products in line with customer expectations and future requirements.
For a full list of v2019 updates, including comprehensive product descriptions, please visit https://www.acdlabs.com/whatsnew.